Specific amino acid dependency regulates the cellular behavior of melanoma

Journal of Nutrition

Volumn 137, Issue 6, 2007, Pages

  Fu, Ya Min ^a   Meadows, Gary G ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; PHENYLALANINE; TYROSINE;

AMINO ACID METABOLISM; APOPTOSIS; CANCER INVASION; CANCER RESEARCH; CELL FUNCTION; CONFERENCE PAPER; HUMAN; MELANOMA; MELANOMA CELL; METABOLIC REGULATION; NONHUMAN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 34249785387     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/137.6.1591s     Document Type: Conference Paper

References (71)

1. American Cancer Society. American Cancer Society Cancer Facts and Figures 2006. Atlanta (GA): American Cancer Society; 2006.
2. Elstad CA, Meadows GG, Abdallah RM. Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction. Clin Exp Metastasis. 1990;8:393-416.
3. Ge X, Fu Y-M, Li Y-Q, Meadows GG. Activation of caspases and cleavage of Bid are required for tyrosine and phenylalanine deficiency-induced apoptosis of human A375 melanoma cells. Arch Biochem Biophys. 2002;403:50-8.
4. Pelayo BA, Fu Y-M, Meadows GG. Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors. Clin Exp Metastasis. 1999;17:841-8.
5. Pelayo BA, Fu Y-M, Meadows GG. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. Int J Oncol. 2001;18:877-83.
6. Fu Y-M, Yu Z-X, Pelayo BA, Ferrans VJ, Meadows GG. Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency. Cancer Res. 1999;59:758-65.
7. Fu Y-M, Yu Z-X, Ferrans VJ, Meadows GG. Tyrosine and phenylalanine restriction induces G0/G1 cell cycle arrest in murine melanoma in vitro and in vivo. Nutr Cancer. 1997;29:104-13.
8. Fu Y-M, Zhang H, Ding M, Li Y-Q, Fu X, Yu Z, Meadows GG. Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin/focal adhesion kinase pathway and actin cytoskeleton remodeling. Clin Exp Metastasis. 2004;21:587-98.
9. Fu Y-M, Yu ZX, Li Y-Q, Ge X, Sanchez PJ, Fu X, Meadows GG. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr Cancer. 2003;45:60-73.
10. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 1998;50:197-263.
11. Seftor REB, Seftor EA, Hendrix MJC. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev. 1999;18:359-75.
12. Parise LV, Lee JW, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol. 2000;10:407-14.
13. Tsuji T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K, Irimura T. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Metastasis. 2002;19:127-34.
14. Laidler P, Gil D, Pituch-Noworolska A, Ciolczyk D, Ksiazek D, Przybylo M, Litynska A. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines. Acta Biochim Pol. 2000;47:1159-70.
15. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis. 2002;19:427-36.
16. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA. 1992;89:5192-6.
17. FAK in platelets. J Cell Biol. 1992;119:905-12.
18. Juliano RL, Haskill S. Signal transduction from the extracellular matrix. J Cell Biol. 1993;120:577-85.
19. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19:5606-13.
20. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003;160:753-67.
21. Kahana O, Micksche M, Witz IP, Yron I. The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene. 2002;21:3969-77.
22. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer. 2002;2:133-42.
23. Kulkarni SV, Gish G, van der Geer P, Henkemeyer M, Pawson T. The role of p120 Ras-GAP in directed cell movement. J Cell Biol. 2000;149:457-69.
24. Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, Fujiwara K. Rhokinase-mediated contraction of isolated stress fibers. J Cell Biol. 2001;153:569-83.
25. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279: 509-14.
26. Kraynov VS, Chamberlain C, Bokoch GM, Schwartz MA, Slabaugh S, Hahn KM. Localized Rac activation dynamics visualized in living cells. Science. 2000;290:333-7.
27. Meili R, Firtel RA. Two poles and a compass. Cell. 2003;114:153-6.
28. Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A. Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res. 2002;62:4484-90.
29. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227-38.
30. Hynes RO. Structural biology. Changing partners. Science. 2003;300:755-6.
31. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activate protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001;12:397-408.
32. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui P-Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996;134:793-9.
33. Xiong W, Parsons JT. Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase. J Cell Biol. 1997;139:529-39.
34. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA. Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol. 1996;135:1383-90.
35. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87:629-38.
36. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 1995;92:4507-11.
37. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 1996;56:1851-4.
38. Wang H-G, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L III, Troppmair J, et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene. 1994;9:2751-6.
39. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-20.
40. Green DR, Evans GI. A matter of life and death. Cancer Cell. 2002;1:19-30.
41. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74:589-607.
42. Zang M, Hayne C, Luo Z. Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J Biol Chem. 2002;277:4395-405.
43. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, Glass DJ. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science. 1999;286:1738-41.
44. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996;87:589-92.
45. Gilmore AP, Metcalfe AD, Romer LH, Streuli CH. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J Cell Biol. 2000;149:431-45.
46. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-XL. Cell. 1996;87:619-28.
47. Hale AJ, Smith CA, Sutherland LC, Stoneman VEA, Longthorne VL, Culhane AC, Williams GT. Apoptosis: molecular regulation of cell death. Eur J Biochem. 1996;236:1-26.
48. Gross A, McDonnell J, Korsmeyer S. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-911.
49. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis. 2003;20:531-9.
50. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-6.
51. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441-6.
52. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CYJ, Sasaki T, Ella AJ, Cheng H-Y, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410:549-54.
53. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science. 2002;298:1587-92.
54. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer. 2000;83:800-10.
55. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol. 2005;15:247-53.
56. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100:826-33.
57. Marten NW, Burke EJ, Hayden JM, Straus DS. Effect of amino acid limitation on the expression of 19 genes in rat hepatoma cells. FASEB J. 1994;8:538-44.
58. Tang DG, Li L, Chopra DP, Porter AT. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res. 1998;58:3466-79.
59. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1999;96:2110-5.
60. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA. 2000;97:3207-12.
61. Meadows GG, Zhang H, Ge X. Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines. J Nutr. 2001;131:S3047-50.
62. Meadows GG, Ge X, Zhang H, Oros DE, Fu Y-M. Inhibition of invasion and metastasis during specific amino acid restriction associated with metastasis suppressor and other gene changes. In: Welch DR, editor. Cancer metastasis-related genes. 3rd vol. Dordrecht (The Netherlands): Kluwer Academic Publishers; 2002. p. 191-208.
63. Wasa M, Bode BP, Souba WW. Adaptive regulation of amino acid transport in nutrient-deprived human hepatomas. Am J Surg. 1996;171:163-9.
64. Poirson-Bichat F, Gonfalone G, Bras-Goncxalves RA, Dutrillaux B, Poupon MF. Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. Br J Cancer. 1997;75:1605-12.
65. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, et al. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res. 1998;58:2583-7.
66. Lu S, Chen GL, Ren C, Kwabi-Addo B, Epner DE. Methionine restriction selectively targets thymidylate synthase in prostate cancer cells. Biochem Pharmacol. 2003;66:791-800.
67. Epner DE. Can dietary methionine restriction increase the effectiveness of chemotherapy in treatment of advanced cancer? J Am Coll Nutr. 2001;20 Suppl 5:S443-9.
68. Gupta A, Miki K, Xu M, Yamamoto N, Moosa AR, Hoffman RM. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res. 2003;23:1181-8.
69. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR, et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 2001;61:6805-10.
70. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, Tan Y, Schold SC. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res. 2001;61:4017-23.
71. Yamamoto N, Gupta A, Xu M, Miki K, Tsujimoto Y, Tsuchiya H, Tomita K, Moosa AR, Hoffman RM. Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overeproducing lung cancer cells. Cancer Gene Ther. 2003;10:445-50.